Three companies reported on the same day, 22 October 2026, and described two different economies. Lam Research makes the machines that build computer chips. It told investors its own revenue forecast would have been higher if it could get parts. Dow and Union Pacific are protecting profit by cutting costs and watching fuel and energy bills.123
Chips: demand ahead of supply
Lam reported what its CEO, Timothy Archer, called record revenue and profitability. Operating margin, the share of each sales dollar left after running costs, topped 40% for the first time.1 Archer said Lam's preliminary 2027 outlook for wafer fab equipment is “more than $200 billion of spending.” He said the growth is led by memory chips (DRAM), then leading-edge foundry and logic, then NAND.1 Wafer fab equipment is the machinery used to build chips.
The most telling words came from Lam's finance chief, Douglas Bettinger. For the December quarter he guided to “revenue of $8.6 billion, plus or minus $400 million,” with earnings per share of $2.33, give or take $0.15.1 Then he added: “This revenue guide would have been a bit higher, if not for some near-term supply chain constraints that we are actively managing.”1
Asked how big unconstrained demand might be, Bettinger declined to give a figure. “I'm not going to put a number on what the unconstrained demand would be,” he said, though he indicated it would be higher.1 That caution is worth noting. The company is saying demand exceeds what it can ship, but it is not putting a number on the gap.
Lam's place in the chain is part of the story. Our entity data records it as a supplier to hyperscalers, the giant cloud companies. It lists Applied Materials and ASML Holding among its competitors.4 The dossier does not say how much of any index fund Lam makes up, so we won't guess whether you own it through one.
Chemicals: self-help, not a boom
Dow reported net sales up 13% from a year earlier, with growth in every operating segment, and operating EBITDA of more than $1.5 billion.2 EBITDA is a rough measure of operating profit before interest, tax and accounting charges. CEO Karen Carter said the company's “Transform to Outperform” programme is on track for about $700 million of improvements this year. It includes cutting about 4,500 Dow roles, around 70% of which have already been carried out.2
Jeffrey Tate repeated the broader target: “we remain focused on our commitment to implement approximately $1.3 billion in net benefits this year as well as $1.3 billion in 2027.”2 He said selling, administrative and R&D costs were “actually down $130 million” from the previous quarter.2 The $1.3 billion is about 3% of Dow's $39.968 billion annual revenue in 2025, so this is a meaningful trim but not a transformation.5
Tate also set out what he expects for the fourth quarter:
- Normal seasonal weakness “will be largely offset by more than $100 million of lower sequential turnaround spending,” meaning less money spent on planned plant shutdowns.2
- Global polyethylene integrated margins are expected to improve by “approximately $0.02 per pound compared to the third quarter.”2
- Third-quarter free cash flow was “$1.1 billion.”2
He was blunt about the backdrop: “Persistently high energy costs continue to challenge industry economics.”2 On the balance sheet he said, “We have approximately $14 billion of liquidity and no substantive debt maturities until 2029.”2
What the filings say about why Dow needs the cost cuts
Dow's audited numbers show why management is leaning on savings. Revenue fell from $44.622 billion in 2023 to $42.964 billion in 2024 and $39.968 billion in 2025, a drop of about 7% in the last year.5 Cash generated by operations fell sharply, from $5.196 billion to $2.914 billion and then $1.032 billion.5 Earnings per share went from $0.82 in 2023 to $1.57 in 2024, then to a loss of $3.70 per share in 2025.5
Dow also gave itself some room. Cash on hand was $3.816 billion at the end of 2025 and $4.110 billion at the end of the first quarter of 2026.5 The share count rose from 703.8 million at the end of 2024 to 717.5 million at the end of 2025.5 Management's plan is therefore to recover profit from a weaker base through costs, not through stronger demand.
Rail: record profit, with fuel as the pressure
Union Pacific's quarter looks strong on the surface. CEO Vincenzo Vena said net income totalled $2.1 billion and adjusted earnings per share grew 15% to $3.53, on “6% volume growth.” He also noted, “Higher fuel prices were a big cost driver.”3
CFO-level detail shows how big. Jennifer Hamann said, “Fuel expense grew 69% on a 64% increase in average fuel price,” from $2.56 to $4.21 per gallon.3 The railroad affirmed high-single-digit 2026 earnings growth while lifting 2026 capital spending to $3.5 billion.3 It is also building a cash cushion ahead of a deal with a rival: “We will continue growing our cash reserves in anticipation of closing the Norfolk Southern merger in the second half of 2027.”3
How reliable is this reporting?
Our three main sources are earnings-call summaries distributed by NewsEOD. Our own measurement of that source found that 60% of 1,107 checked claims held up.123 That is a useful signal but not a clean bill of health, and it is why we lean on the direct quotes and the SEC-filing numbers for Dow. The summaries also cut off some passages mid-sentence, so we have not extended any statement beyond what is quoted. We also hold no detail on the CFO changes at Rivian and Union Pacific, so we make no claim about them.
Our read, and what to watch
Via News's analysis of this material is that the split is real but narrower than it first looks. Lam's constraint is on the supply side, which means demand is not the problem. Dow and Union Pacific face cost pressure, and each has a plan to manage it. The two stories share one risk, which is how long energy and fuel costs stay high.
- Lam's supply constraints. Watch for any figure on how much the shortage held back its forecast. Bettinger has declined to give one so far.1
- Dow's fourth quarter. The test is whether the $1.3 billion of savings shows up in profit and whether polyethylene margins improve as Tate expects.2
- Ivonescimab. The FDA has set a target decision date of 14 November 2026 for Summit Therapeutics' application.6
- Origin Bancorp. After crossing $10 billion in assets, it expects the Durbin Amendment to cut fee income by $4 million to $4.5 million from mid-2027.6
